Metastasis is a leading cause of mortality for cancer patients, yet the molecular mechanisms underlying metastasis are still poorly understood. It was established more than 100 years ago that particular tumor types have a propensity to metastasize to certain organs (Paget, 1889) ; for example, breast tumor cells tend to metastasize to lung, bones, brain, and liver. We now know that this nonrandom distribution of metastases is independent of vascular anatomy, rate of blood flow, and the number of tumor cells delivered to each organ (Fidler, 2003) . Instead, metastases may be due to expression of particular genes within the tumor cells that drive their invasion of a particular organ (Kang et al., 2003; Minn et al., 2005) . Cancer cells must succeed in multiple feats to successfully seed a new tissue site. First, they escape from the primary tumor and invade local tissue; then, they enter the bloodstream or lymphatic system where they must survive; finally, they move from the blood stream into tissues (extravasation) that are far from the primary tumor site and adapt to or modify the metastatic niche to establish a new tumor. In this issue, Padua et al. (2008) discover that the growth factor TGFβ primes human tumor cells for lung metastasis by driving expression of the adipokine angiopoietin-like 4 (ANGPTL4), which enables the tumor cells to extravasate into the lung by disrupting capillary vascular endothelial cell junctions.
Although most studies exploring the molecular mechanisms of metastasis have focused on features intrinsic to tumor cells, the tumor microenvironment also plays an important role (McSherry et al., 2007) . Primary carcinomas, as well as metastases, are comprised of both tumor cells and cells of the stroma including fibroblasts, endothelial cells, and inflammatory cells (Figure 1 ). There is strong evidence that interactions between the tumor cells and the stroma influence cancer growth and metastasis (Karnoub et al., 2007; Lin et al., 2001; Olumi et al., 1999) . One accepted role for stromal cells during metastasis is to enhance the ability of tumor cells to leave the primary tumor and to invade local tissue. However, extravasation and tumor establishment at sites distant from the primary tumor are limiting steps of metastasis, and the ways in which the primary tumor microenvironment may promote these later stages of metastasis is still unclear.
One factor that is produced abundantly by stromal cells in the tumor microenvironment is transforming growth factor β (TGFβ). TGFβ is a multifunctional growth factor with a complicated dual role in tumorigenesis (Leivonen and Kahari, 2007) .
The microenvironment of a tumor is known to influence tumor progression and spread to distant sites (metastasis). Padua et al. (2008) now show that transient exposure of breast cancer cells to the signaling molecule transforming growth factor β (TGFβ) promotes their extravasation from blood vessels and entry into the lung by upregulation of the adipokine angiopoietin-like 4 (ANGPTL4). Their work shows that the later stages of metastasis can be influenced by transient signals produced in the primary tumor microenvironment.
Figure 1. TGFβ Influences Tumor Growth and Metastasis
The cytokine TGFβ is produced by stromal cells of the tumor microenvironment in response to hypoxia or inflammation, or by carcinoma-associated fibroblasts (CAFs). Cancer cells in advanced tumors are unresponsive to the growth inhibitory effects of TGFβ and instead respond to this factor by increasing their growth, survival, motility, and invasion, and by undergoing an epithelial-to-mesenchymal transition (EMT). In addition to these effects, TGFβ stimulates expression of the adipokine angiopoietin-like 4 (ANGPTL4) by activating SMAD transcription factors. Secretion of ANGPTL4 enables tumor cells to extravasate into lung tissue and to seed micrometastases.
During the early stages of tumor formation, TGFβ acts as a tumor suppressor, inhibiting proliferation and inducing apoptosis of tumor cells. During later stages of tumorigenesis, however, many tumor cells become unresponsive to the growth inhibitory functions of TGFβ, and instead respond to this growth factor by becoming more motile, more invasive, and more resistant to apoptosis. Furthermore, TGFβ is induced in response to hypoxia and inflammation and can have a protective effect on tumor cells. TGFβ has also been observed to drive an epithelial-to-mesenchymal transition in cancer cells, which increases their metastatic capability.
In their new study, Padua et al. (2008) examine the role of TGFβ produced by stromal cells in the metastasis of breast tumor cells to the lung. The authors used a gene-expression microarray approach to define a group of target genes expressed by human breast tumor cells in response to TGFβ exposure. They found that the TGFβ-response signature (TBRS) correlated with metastasis to lung tissue in patients with estrogen receptor (ER)-negative breast cancer. No link was identified between the TBRS and metastasis to bone, or metastasis of ER-positive breast tumor cells.
Comparison of gene-expression profiles between the TBRS and a lung metastasis signature (LMS) (Minn et al., 2005) revealed that ER-negative breast tumors scoring positive for both the TBRS and the LMS were uniquely associated with a high risk of lung metastasis. To test the requirement for TGFβ in metastasis of ER-negative breast cancer cells, the authors turned to an ER-negative human breast cancer cell line, LM2, which had been selected experimentally for the capability to metastasize to lung (Minn et al., 2005) . Blocking TGFβ signaling led to reduced metastasis to the lungs of recipient mice, but did not affect tumor growth or intravasation. These data suggest that TGFβ is critical for ER-negative breast tumor cells to complete one or more of the later stages of metastasis, that is, survival in the bloodstream, extravasation, or colonization of the lungs.
Experimental metastasis assays, which involve direct inoculation of tumor cells into the bloodstream of mice, measure the ability of cells to extravasate, and colonize a distant organ. The authors asked whether prior exposure of ER-negative human breast tumor cells to TGFβ in vitro could influence the ability of the tumor cells to complete the final steps of metastasis to lung. Treatment of the tumor cells with TGFβ for a short time prior to intravenous injection into mice significantly increased the number of cells detected in the lung in the first 24 hr after inoculation. Because this effect was not sustained through outgrowth of metastatic colonies, the data suggested that TGFβ selectively primes tumor cells for extravasation to lung.
Analysis of two genes whose expression overlapped between the TBRS and the LMS profiles led the authors to identify ANGPTL4 as a possible mediator of TGFβ-mediated lung colonization. TGFβ signaling induced expression of ANGPTL4 in a number of cultured tumor cell lines, and also in primary malignant pleural cell effusion samples from breast cancer patients. Remarkably, blocking ANGPTL4 expression using short hairpin RNAs inhibited lung metastases from LM2 breast cancer cell xenografts in mouse mammary glands. The investigators showed that this effect was due to decreased extravasation of the tumor cells into the lung. Secretion of ANGPTL4 by the breast cancer cell line led to disruption of junctions between vascular endothelial cells, causing increased permeability of lung capillaries. Together, these results suggest that exposure to TGFβ produced by the stroma imbues ERnegative breast cancer cells with the ability to form metastatic lesions when they reach the lung. Interestingly, exposure of breast tumor cells to TGFβ had no effect on their ability to colonize bone following injection into the arterial circulation of recipient mice, presumably because of the absence of vascular endothelial junctions in the bone marrow vasculature.
Just as multiple steps are required for tumor formation, it is likely that tumor progression and metastasis are a result of multiple gene products acting in concert with one another. The Padua et al. study demonstrates how the elegant strategy of gene-expression profiling combined with clinical outcome information (Bild et al., 2006) can shed light on the role of stromal components of the tumor microenvironment in metastasis. By focusing on critical downstream elements of TGFβ signaling during metastasis, the authors have identified a functional role for ANGPTL4 in the extravasation step that enables breast tumor cells to colonize lung tissue.
The pleiotropic roles of TGFβ serve as an excellent example of how a functional gain in a given signaling pathway in the primary tumor can provide a selective advantage both in primary tumor growth and in the development of distant metastases. Even if the upregulation of ANGPTL4 is an incidental "side effect" of exposure to TGFβ in the primary tumor, it clearly provides an advantage to tumor cells at later stages of tumorigenesis and metastasis. Given that the effects of TGFβ and ANGPTL4 on metastasis were specific for ER-negative breast tumor cells, it is likely that there are additional cooperating factors that contribute to this process. Interestingly, mesenchymal stem cells can also stimulate extravasation of the same ER-negative breast cancer cell line by upregulating the chemokine CCL5 (Karnoub et al., 2007) . Together, these studies provide new compelling evidence that metastasis is regulated by contextual signals that tumor cells receive from their microenvironment.
